ABSTRACT 1 BACKGROUND: Anoctaminopathies are muscle diseases caused by recessive mutations 2 in the ANO5 gene. The effects of anoctaminopathy on oxidative capacity have not
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Increase of lactate increases ventilation, which can be measured as increase of ventilatory 4 equivalent for O2 and CO2 (VE/O2% and VE/CO2) and decrease of fraction of end tidal 5 CO2 (FetCO2%). In the patients, VE/O2% and VE/CO2% were increased and FetCO2% 6
decreased. This could have been interpreted as increased anaerobic metabolism, suggesting 7 patients' exercise tests to be more maximal than those of the controls. By controlling 8 spiroergometric variables for maximal lactate levels in addition to BMI, we could see that 9
the level of exercise of the patients was not greater than in the controls. Before these 10 calculations, we had analyzed the behavior of lactate and ammonia associated with exercise, 11 and no specific findings were seen. The respiratory quotient, RQ, could also have been 12 used to control for the level of exercise. However, maximal lactate level serves here better 13 as adjustment because, in contrast to RQ, lactate is not a spiroergometric variable itself. 14 15
Muscle MRI 16
MRI was performed using a 1.5 T Siemens system. Axial images were acquired for the 17 pelvic, thigh, and leg muscles. The pulse sequences were T1-weighted spin echo (SE) with 18 TR of 600 to 700 ms, TE of 15 ms, and a STIR fat suppression sequence with TR of 3200 19 to 4300 ms, TE of 33 ms, and an inversion time (TI) of 160 ms. Slices of 7 mm were used. 20
The involvement of each muscle was scored on a scale of 0 to 3, where 0 indicated normal, 21
(quadriceps femoris, adductors, hamstrings, sartorius, and gracilis) and lower leg (tibialis 1 posterior, peroneus, deep posterior compartment, soleus, and gastrocnemius). Based on 2 five leg and thigh muscles, the maximum aggregated score was 15. Follow-up scans were 3 performed using the same scanner and identical parameters for patients 1 (2 years between 4 scans), 2 (4 years between scans), 4 (2 years between scans), 7 (2 years between scans), 9 5 (2 years between scans), and 13 (12 years between scans). 6
7

RESULTS
8
Screening of the ANO5 gene 9
We sequenced the ANO5 coding regions and flanking intron sequences in 111 patients with 10 suspected myopathy of an undetermined cause based on symptoms and clinical findings, 11 an elevated CK, myopathic electromyography (EMG), muscle biopsy, or muscle MRI. We 12 identified 12 patients from 10 families as positive for ANO5 variants (Table 2) . Clinical 13 and genetic data from patients 13 and 14 were previously reported [1, 2, 8] . 14 
15
The most common genetic finding was homozygous ANO5 c.2272C>T (p.Arg758Cys). 16 Eight patients were homozygous for this variant, while the remaining four were compound 17 heterozygous for p.Arg758Cys in combination with either c.191dupA (p.Asn62LysfsX15), 18 c.1409T>G (p.Met470Arg), or c.1664G>T (p.Ser555Ile) ( Despite being relatively genetically homogeneous, our anoctaminopathy series showed 5 some variability in clinical features ( Table 2 ). Six of our 14 patients were female. The age 6 of reported symptom onset ranged from 12 to 62 years, with an average age of 33 for female 7 patients (SD 5.9 years) and 31 for male patients (SD 16 years). The disease duration ranged 8 from 6 to 58 years. At onset, three patients complained of muscle pain, unpleasant muscle 9 sensations in the calves, and cramps. Six patients initially experienced difficulty walking 10 on their tiptoes, two patients complained of difficulty climbing stairs, and two patients 11 complained of difficulty running and climbing stairs. One patient reported no muscle 12 symptoms and an increased CK was found incidentally. During the course of the disease, 13 muscle pain, stiffness, or cramps were common among all patients. Clinical examination 14 showed distal lower limb muscle involvement in six patients, proximal involvement in two 15 patients, and both distal and proximal involvement in six patients. 16 Plasma CK ranged from 240 to 12,290 IU/l. EMG findings were myopathic in 7 out of 12 17 patients tested. Four patients exhibited both neurogenic and myopathic features, whereas 18 one patient had a normal EMG (Table 2 ). Muscle biopsies were obtained from 13 patients. 19 The findings ranged from necrotizing myopathy or strong dystrophic changes to mild 20 atrophy of type 2 fibers. Three out of nine patients who underwent cardiac ultrasound had 21 slightly abnormal findings primarily attributed to hypertension (Table 2) . ECGs showed 22 normal findings for all patients (Table 4) . 23
Skeletal muscle imaging 1 Table 3 summarizes the muscle MRI findings. Muscle T1-weighted MRI scans showed 2 fatty replacement predominantly in the adductors, hamstrings, gastrocnemius, and soleus. 3
Muscle MRI STIR-weighted scans showed hyperintensities suggesting myoedema 4 primarily in the hamstrings, quadriceps, adductors, gastrocnemius, and soleus. These 5 findings were more evident at the early stages of disease. Table 1 shows the anthropometric and spirometric characteristics for patients and controls. 16 During the exercise test, patients with anoctaminopathy exhibited a significantly lower 17 maximal working capacity (Wmax/3min), maximum oxygen uptake (VO2max), oxygen 18 pulse (V'O2/HR), and mechanical efficiency (Wmax/V'O2max) than those for controls 19 (Table 4) . However, the respiratory quotient (V'CO2/V'O2) tended to be higher in patients, 20 and signs of increased ventilation demonstrated by a significantly increased ventilatory 21 equivalent for O2 (VE/V'O2) and CO2 (VE/V'CO2) in addition to a decreased fraction of 22 end-tidal CO2 (FetCO2) were seen in patients compared to controls. 23
In the blood gas analyses, patients exhibited the lowest blood pH of 7.3 at 2 to 6 min and 1 the lowest base excess (BE) -5.5 mmol/l at 6 min after exercise, while the corresponding 2 values in controls were pH of 7.26 at 2 min and BE -7.77 mmol/l at 4 min after exercise. 3
For the BE values, we found a significant difference between patients and controls at 2 and 4 4 min after exercise (p = 0.039 and 0.013, respectively), and a significant difference in the 5 pH values at 2 min after exercise (p = 0.048). In addition, we found significantly lower 6 lactate readings in patients compared to controls (p = 0.049) at 2 and 4 min after exercise. 7
However, we found no difference between patients and controls in the levels of ammonia 8 ( Figure 2 ). 9
We studied a cohort of patients with ANO5-related dystrophy, providing a detailed clinical 12 analysis. Anoctaminopathy has been reported in several countries, including Canada [2] , 13 the UK and Germany [6, 14] , Finland [1, 3] , the Netherlands [2, 15] , Denmark [5] , the 14 Czech Republic [16] , and Italy and other countries in Europe and worldwide [17] [18] [19] . We 15 found that 11% of our suspected LGMD patients had ANO5 mutations, supporting that they 16 are a common cause of myopathy in northern Europe. 17 
18
We found the variant c.2272C>T (p.Arg758Cys) in all of our patients, appearing as 19 homozygous in 10 patients from 8 families and as compound heterozygous with another 20 variant in 4 patients from 3 families. This finding is not surprising since c.2272C>T has a 21 carrier frequency of 0.35% in Finland, thus explaining most known Finnish cases [3] . 22 Among the compound heterozygous patients, one had the c.191dupA (p.Asn62Lysfs15X) 23 variant, which is common in other Northern European populations [14] . One patient had 1 the c.1664G>T (p.Ser555Ile) variant, which was recently found in the heterozygous state 2 in a patient sequenced as part of a cohort of patients with LGMD or unspecified myopathy 3 [17] . Bioinformatic predictions support the pathogenicity of this variant. However, since 4 carriers are found in European populations, it is likely that a second hit is necessary on the 5 other allele for this variant to cause disease, as was the case in our patient. Finally, two 6 siblings (Family J, patients 11 and 12) presented with previously unknown variant 7 c.1409T>G (p.Met470Arg). This variant received high scores for pathogenicity using 8 bioinformatics tools, and was not found in public exome databases. 9
10
The clinical findings in our anoctaminopathy patients correspond to previous descriptions, 11 featuring asymmetric proximal or distal muscle involvement and myalgia [1-3, 5, 6, 14-12 20] . We found a tendency towards asymmetric muscle involvement, a feature of 13 anoctaminopathy not typically reported for other forms of LGMD [2, 21] documented an association between being male and anoctaminopathy [3, 14, 15, 22] .
However, we found no significant difference in the average age of disease onset based on 1 gender, although the variance for the age of onset was greater among the men in our study. results presented here further demonstrate that fatty degeneration tends to increase as the 8 disease progresses. Therefore, T1-weighted MRI may be useful as a follow-up tool or as 9 an assessment tool for potential treatment. The STIR technique is a sensitive tool in early 10 diagnostics, but not in the later stages of disease. Furthermore, EMG results remain 11 variable, featuring both myopathic and neurogenic findings. 12 
13
To our knowledge, this is the first study to explore the oxidative capacity of 14 anoctaminopathy patients compared to an anthropometrically matched control population. 15 Patients with anoctaminopathy showed significantly lower oxygen uptake than controls, 16 which may serve as a primary feature of the disease or secondary to deconditioning 17 provoked by muscle weakness and pains. Additionally, the patients' oxygen pulse 18 (V'O2/HR) was lower than controls, most likely associated with the diminished capacity 19 of the peripheral muscles [23, 24] . The level of maximal oxygen uptake reported here 20 corresponds to that measured by Vissing et al [9] before regular aerobic training.
In patients, we found an excess of ventilation accompanied an increase in the ventilatory 1 equivalents for O2 and CO2. In addition, more than half (7/12 patients) had FetCO2 lower 2 than 4.5% during maximal exercise suggesting slight hyperventilation. By contrast, 3 controls showed normoventilation, although we expected them to display a stronger 4 respiratory compensation due to stronger metabolic acidosis associated with exercise 5 compared to patients. The spirometric findings did not explain this inconsistency. The 6 forced vital capacity (FVC) was slightly lower in patients than in healthy controls, but only 7 one patient (patient 9) developed restrictive ventilatory impairment (FVC < 80% of the 8 predicted value), suggesting that ventilatory function was not the cause of the increased 9 ventilation. The increased ventilation might be explained by the lowered aerobic exercise 10 capacity of the muscles leading to secondary hyperventilation during exercise. In addition, 11 the reduced mechanical efficiency (Wmax/V'O2max) most likely reflected this finding, 12
indicating an increased need for oxygen uptake related to the attained workload. 13 
14
Patients' lactate and ammonia levels tended to be lower than those among controls. This 15 might be explained by the lower exercise capacity due to muscle disease. However, the RQ 16 levels of patients tended to be higher than those among controls indicating at least the same 17 level of aerobic capacity among both patients and healthy controls. We should note that an 18 increase in ventilation may partly explain the elevated RQ levels we observed in patients. 19 We found no specific findings or indications of metabolic muscular myopathy. 20 
21
In conclusion, our report confirms the importance of the recessive ANO5 variants as causes Table 4 . Spiroergometric data for patients with ANO5 and healthy controls. AT = anaerobic threshold, Wmax/3 min = mean workload during the last 3 min of exercise, maximal V'O2max = maximal oxygen uptake, VECO2 = ventilatory equivalent for CO2 production, VEO2 = ventilatory equivalent for O2 uptake, Wmax/V'O2 max = mechanical efficiency. Comparisons were controlled for the maximal lactate levels and BMI. Level of significance after Bonferroni correction is P < 0.003. 
